12.69
0.05 (0.40%)
| Penutupan Terdahulu | 12.64 |
| Buka | 12.64 |
| Jumlah Dagangan | 1,694,691 |
| Purata Dagangan (3B) | 2,320,288 |
| Modal Pasaran | 1,641,931,136 |
| Harga / Jualan (P/S) | 2.31 |
| Harga / Buku (P/B) | 1.98 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 Oct 2025 |
| Margin Keuntungan | -11.54% |
| Margin Operasi (TTM) | -16.56% |
| EPS Cair (TTM) | -0.610 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 7.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 68.08% |
| Nisbah Semasa (MRQ) | 2.05 |
| Aliran Tunai Operasi (OCF TTM) | 7.61 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -2.21 M |
| Pulangan Atas Aset (ROA TTM) | -2.75% |
| Pulangan Atas Ekuiti (ROE TTM) | -8.56% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Menaik | Menaik |
| Diagnostics & Research (Global) | Menaik | Menaik | |
| Stok | NeoGenomics, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.00 |
|
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.19% |
| % Dimiliki oleh Institusi | 98.21% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| American Capital Management Inc | 30 Sep 2025 | 2,345,263 |
| Julat 52 Minggu | ||
| Median | 14.00 (10.32%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Needham | 12 Jan 2026 | 14.00 (10.32%) | Beli | 12.49 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| OLIVO ALICIA C | - | 12.93 | -15,145 | -195,825 |
| STONE WARREN | - | 12.93 | -15,127 | -195,592 |
| Jumlah Keseluruhan Kuantiti Bersih | -30,272 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -391,417 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 12.93 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| OLIVO ALICIA C | Pegawai | 13 Jan 2026 | Dibuang (-) | 15,145 | 12.93 | 195,825 |
| OLIVO ALICIA C | Pegawai | 13 Jan 2026 | Pelaksanaan pilihan | 59,382 | - | - |
| STONE WARREN | Pegawai | 13 Jan 2026 | Dibuang (-) | 15,127 | 12.93 | 195,592 |
| STONE WARREN | Pegawai | 13 Jan 2026 | Pelaksanaan pilihan | 59,382 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Jan 2026 | Pengumuman | NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue |
| 05 Jan 2026 | Pengumuman | NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
| 30 Dec 2025 | Pengumuman | NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors |
| 15 Dec 2025 | Pengumuman | NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation |
| 10 Dec 2025 | Pengumuman | NeoGenomics to Present New ctDNA Research at SABCS 2025 |
| 08 Dec 2025 | Pengumuman | NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025 |
| 06 Nov 2025 | Pengumuman | NeoGenomics to Participate in Upcoming Investor Conferences |
| 30 Oct 2025 | Pengumuman | NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors |
| 28 Oct 2025 | Pengumuman | NeoGenomics Reports Third Quarter 2025 Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |